CFGS
VRTX icon

Concourse Financial Group Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Concourse Financial Group Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,677
Closed -$2.86M – 2037
2024
Q4 		$2.86M Buy
6,677
+1,786
+37% +$828K 0.16% 132
2024
Q3 		$2.27M Sell
4,891
-22
-0.4% -$10.6K 0.14% 157
2024
Q2 		$2.3M Buy
4,913
+89
+2% +$38.6K 0.14% 150
2024
Q1 		$2.02M Buy
4,824
+710
+17% +$300K 0.13% 164
2023
Q4 		$1.67M Buy
4,114
+1,301
+46% +$481K 0.12% 177
2023
Q3 		$978K Buy
2,813
+264
+10% +$92.3K 0.08% 262
2023
Q2 		$897K Buy
2,549
+107
+4% +$36.1K 0.07% 296
2023
Q1 		$769K Buy
2,442
+623
+34% +$187K 0.06% 330
2022
Q4 		$525K Buy
1,819
+554
+44% +$169K 0.04% 403
2022
Q3 		$366K Sell
1,265
-324
-20% -$93.2K 0.03% 419
2022
Q2 		$448K Sell
1,589
-1,425
-47% -$381K 0.04% 418
2022
Q1 		$787K Sell
3,014
-3,308
-52% -$785K 0.06% 328
2021
Q4 		$1.39M Buy
6,322
+303
+5% +$58.9K 0.08% 246
2021
Q3 		$1.09M Buy
6,019
+1,616
+37% +$316K 0.07% 290
2021
Q2 		$888K Sell
4,403
-3,375
-43% -$706K 0.06% 327
2021
Q1 		$1.67M Buy
7,778
+2,736
+54% +$601K 0.12% 157
2020
Q4 		$1.19M Buy
5,042
+1,545
+44% +$354K 0.09% 196
2020
Q3 		$952K Buy
3,497
+748
+27% +$206K 0.08% 205
2020
Q2 		$798K Buy
2,749
+1,109
+68% +$301K 0.08% 207
2020
Q1 		$390K Buy
1,640
+552
+51% +$127K 0.04% 302
2019
Q4 		$238K Buy
1,088
+441
+68% +$89.3K 0.02% 463
2019
Q3 		$110K Buy
647
+2
+0.3% +$354 0.03% 420
2019
Q2 		$118K Buy
645
+234
+57% +$40.9K 0.01% 624
2019
Q1 		$75K Buy
411
+282
+219% +$52.1K 0.01% 751
2018
Q4 		$21K Buy
129
+74
+135% +$12.8K ﹤0.01% 1141
2018
Q3 		$11K Buy
+55
New +$9.79K ﹤0.01% 1075

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Concourse Financial Group Securities's VRTX Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 6,677 shares — an estimated $2.86M sold.

Concourse Financial Group Securities first reported a position in VRTX in Q3 2018 and held it in 26 quarters. The position peaked at $2.86M in Q4 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 6,677 Vertex Pharmaceuticals shares in Q1 2025, an estimated $2.86M.
  • Concourse Financial Group Securities first reported a position in Vertex Pharmaceuticals in Q3 2018 and held it in 26 quarters.
  • Concourse Financial Group Securities's Vertex Pharmaceuticals position peaked at $2.86M in Q4 2024.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.